Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JEV-I Co-administered With MMR in Healthy Children
NCT06331702Phase 4Completed
- Sponsor
- Liaoning Chengda Biotechnology Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of japanese encephalitis vaccine (vero cell), inactivated in Japanese encephalitis (JE), sponsored by Liaoning Chengda Biotechnology Co., Ltd.. Started Mar 2024; status: completed.
02
Drugs
japanese encephalitis vaccine (vero cell), inactivated
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT06331702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331702.